Evidence map›Paper›PMID 40615482›Full record

ArticleScientific reports2025

Ring-finger protein RNF126 promotes prostate cancer progression via regulation of MBNL1.

Xin Jiang, Ji Li, Jiali Zhang, Yulei Zhao, Guoqin He, Xiaohui Yao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin Jiang *Baoying People's Hospital, 1 Xincheng Road, Baoying, Yangzhou, 225800, Jiangsu Province, China.
Ji Li *Baoying People's Hospital, 1 Xincheng Road, Baoying, Yangzhou, 225800, Jiangsu Province, China.
Jiali Zhang *Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
Yulei ZhaoNanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, China.
Guoqin HeBaoying People's Hospital, 1 Xincheng Road, Baoying, Yangzhou, 225800, Jiangsu Province, China. jx932578@163.com.
Xiaohui YaoBaoying People's Hospital, 1 Xincheng Road, Baoying, Yangzhou, 225800, Jiangsu Province, China. sciencej06@163.com.

Funding

Beijing Medical Award Foundation YXJL-2024-0299-0065Medical Research Project of Yangzhou Municipal Health Commission 2023-2-23Yangzhou Basic Research Program 2024-2-23
6 · The paper itself

Abstract

purposeAberrant activation/overexpression of RNF126 is implicated as a driving event in tumor progression. However, although some functions of RNF126 in prostate cancer (PCa) cell lines has been reported, more biological functions and in-depth mechanisms should be further clarified in PCa.

methodsHere, we provide evidence that RNF126 expression is elevated in human PCa tissues and cell lines, which is associated with tumor grades and prognosis. Cell proliferation was measured by the CCK8 and colony-formation assays. Cell migration was performed by Transwell and wound-healing assays. RNF126 target proteins were investigated via proteomic, co-immunoprecipitation and western blot methods. Additionally, we knock-downed MBNL1 expression to perform rescue experiments. In vivo, xenograft mice assay was used to verify the effect of RNF126 on the growth of PCa cell.

resultsHere, we showed that RNF126 was highly expressed in PCa and its higher expression was associated with worse patients' prognosis. Expression modulation of RNF126 affects PCa cells proliferation, migration, EMT and docetaxel (DTX) resistance in vitro or in vivo. Additionally, RNF126 involves in the regulation of PI3K/AKT, MEK/ERK and EMT pathways. Mechanistically, immunoprecipitation (IP) and coimmunoprecipitation (co-IP) assays indicated that RNF126 could bind to MBNL1 directly. Our data also suggested that MBNL1 was a critical downstream event in RNF126-mediated tumorigenesis and chemo-resistance and played a crucial role in driving the PI3K/AKT, MEK/ERK and EMT pathways.

conclusionTaken together, our findings reveal a novel biological and molecular functions of RNF126 and may provide a new treatment option for PCa patients.

Indexed as

Prostatic NeoplasmsRNA-Binding ProteinsUbiquitin-Protein LigasesAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudePrognosisRNA-Binding ProteinsRNF126 protein, humanUbiquitin-Protein LigasesChemo-resistanceMBNL1PrognosisProstate cancerRNF126Signaling pathways

Identifiers

PMID40615482
PMCPMC12227677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.